Sidley Austin

1 month ago | outsourcedpharma.com | Emily Marden |Kelly Kasulis Cho |Sidley Austin |Louis Garguilo

By Emily Marden and Kelly Cho, Sidley Austin In recent years, the FDA has communicated a focus on advancing the development of cell and gene therapies (CGT), mirroring industry’s optimism that these therapies can potentially offer durable and targeted treatment options. Such therapies are regulated in the U.S. as biological products by FDA’s CBER and require approval of a biologics license application (BLA) under Section 351 of the Public Health Service Act prior to being marketed.

Nov 25, 2024 | abovethelaw.com | Kathryn Rubino |Sidley Austin

Sidley Austin is the latest firm to cement their place in the top echelon of Biglaw by offering associates top-of-market bonuses. Must be that nifty $3,100,458,000 in gross revenue the firm took down last year. The firm will offer the following bonus schedule for associates, provided they hit they 2,000 hour billable target.

Aug 1, 2024 | abovethelaw.com | Joe Patrice |Sidley Austin

Sidley Austin may be closing offices in China — like a lot of Biglaw these days — but that’s not stopping the firm from setting up in new locales. The firm just opened its fifth California office — it already has two in Los Angeles and two in the Bay Area — in sunny San Diego.

Jan 16, 2024 | corporatecomplianceinsights.com | Sidley Austin

Vaulting past the SEC, which continues to deliberate climate disclosure requirements for public companies, the state of California last year passed two pieces of legislation that impose unprecedented reporting requirements on companies doing business in the state, the world’s sixth-largest economy. A trio of experts from law firm Sidley Austin dig into the details. Maureen F. Gorsen, Heather M. Palmer and Caleb J. Bowers co-authored this article.